Does combination therapy work in chronic thromboembolic pulmonary hypertension?

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Chronic thromboembolic pulmonary hypertension (CTEPH) treatment options are evolving.
• Experience with combination therapy for CTEPH remains limited.
• Understanding long-term survival outcomes is crucial for treatment optimization.

Purpose of the Study:

• To present the first 5-year survival results for dual combination therapy versus monotherapy in CTEPH.
• To compare survival outcomes between different medical therapy strategies in CTEPH patients.
• To evaluate the efficacy of combination therapy in a real-world CTEPH population.

Main Methods:

• Retrospective analysis of consecutive non-operated CTEPH patients receiving PH-specific medical therapy (2002-2019).
• Comparison of survival between monotherapy and dual combination therapy (upfront or sequential) up to 5 years.
• Inclusion of 183 patients (83 monotherapy, 100 combination therapy) with detailed baseline and follow-up data.

Main Results:

• Patients on combination therapy presented with more severe baseline characteristics (higher NT-proBNP, mean pulmonary artery pressure, pulmonary vascular resistance; lower cardiac index).
• Estimated 5-year survival was 79% for monotherapy and 70% for combination therapy.
• No significant difference in survival was observed between the monotherapy and dual combination therapy groups (p=0.22).

Conclusions:

• Dual combination therapy for CTEPH demonstrated comparable 5-year survival to monotherapy.
• These findings suggest combination therapy is a viable option, even in patients with more severe baseline disease.
• Further research may elucidate optimal combination strategies and patient selection for CTEPH treatment.